Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

BACKGROUND: Immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor induce a response in only a subgroup of patients with metastatic melanoma. Previous research suggests that transforming growth factor beta signaling and a collagen-rich peritumoral stroma (tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Daan P, Jensen, Christina, Koolen, Stijn L W, Aerts, Joachim, Karsdal, Morten Asser, Mathijssen, Ron H J, Willumsen, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583811/
https://www.ncbi.nlm.nih.gov/pubmed/33093157
http://dx.doi.org/10.1136/jitc-2020-001193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583811/
https://www.ncbi.nlm.nih.gov/pubmed/33093157
http://dx.doi.org/10.1136/jitc-2020-001193

Ejemplares similares